Glaukos Corporation (GKOS) Market Cap & Valuation Ratios
Glaukos Corporation (GKOS) has a market cap of $10.6B and a price-to-sales ratio of 17.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GKOSGlaukos CorporationFollow GKOS — free
—
Price chart with a free account
- Market cap
- 10.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Peers
medical devices · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| GKOS | 11 | — | 17.0 | — | -0.1% | +42% | -32% | -31% |
| STE | 23 | 28.4 | 4.0 | 14.7 | 4.1% | +8% | 19% | 10% |
| ZBH | 19 | 23.9 | 3.0 | 11.2 | 6.4% | +9% | 14% | 5% |
| PEN | 13 | 79.7 | 8.1 | 59.3 | 1.7% | +18% | 12% | 13% |
| GMED | 11 | 20.9 | 3.3 | 11.2 | 6.9% | +20% | 20% | 12% |
| PODD | 10 | 27.9 | 3.5 | 17.5 | 2.7% | +29% | 17% | 22% |
| BIO | 9.9 | — | 3.7 | 42.7 | 3.6% | +1% | 2% | 0.4% |
| BRKR | 8.8 | — | 3.0 | 52.2 | 1.1% | +2% | -0.9% | -0.7% |
| HAE | 5.4 | 57.3 | 4.7 | 23.5 | 5.4% | +0.4% | 12% | 7% |
| LIVN | 4.5 | 23.9 | 2.9 | 17.6 | 3.3% | +12% | 13% | 14% |
| ITGR | 4.3 | 34.7 | 3.0 | 17.4 | 2.6% | +3% | 10% | 6% |
| Median of these 10 | 28.1 | 3.4 | 17.6 | 3.4% | +8% | 13% | 8% |
; EV/Sales 17.0 vs. 3.4.
Growth vs. price
each dot a company · hover or tap for valuesGKOS and BIO and BRKR have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Glaukos Corporation — questions
- What is Glaukos Corporation's market cap?
- $10.6B.
- What is Glaukos Corporation's price-to-sales ratio?
- 17.2.
Every figure on this page comes from Glaukos Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.